CITATION REPORT List of articles citing

RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study

DOI: 10.1002/gcc.2870020212 Genes Chromosomes and Cancer, 1990, 2, 159-62.

Source: https://exaly.com/paper-pdf/21409285/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	N-ras gene mutations in childhood acute non-lymphoblastic leukemia. <i>Leukemia Research</i> , 1991 , 15, 93	5- <u>4</u> . 1 ⁄7	3
40	Evaluation of the ligase chain reaction (LCR) for the detection of point mutations. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1992 , 283, 119-23		31
39	The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. <i>New England Journal of Medicine</i> , 1994 , 330, 637-9	59.2	33
38	Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. <i>New England Journal of Medicine</i> , 1994 , 330, 597-601	59.2	366
37	Molecular evidence that childhood monosomy 7 syndrome is distinct from juvenile chronic myelogenous leukemia and other childhood myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 50-7	5	17
36	Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. <i>Leukemia Research</i> , 1997 , 21, 697-701	2.7	43
35	The non-random distribution of point mutations in leukaemia and myelodysplasiaa possible pointer to their aetiology. <i>Leukemia Research</i> , 1997 , 21, 559-74	2.7	17
34	RAS mutations in pediatric leukemias with MLL gene rearrangements. 1998 , 21, 270-275		27
33	Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. <i>Blood</i> , 2000 , 96, 1655-1669	2.2	248
32	Treatment-related leukaemiaa clinical and scientific challenge. <i>Cancer Treatment Reviews</i> , 2000 , 26, 377-91	14.4	20
31	Acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 2001, 62-86	3.1	90
30	Molecular targets in acute myelogenous leukemia. <i>Blood Reviews</i> , 2003 , 17, 15-23	11.1	29
29	A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. <i>Cancer Gene Therapy</i> , 2003 , 10, 745-54	5.4	6
28	Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. <i>Leukemia</i> , 2003 , 17, 1482-98	10.7	36
27	Mutational profiling in the human genome. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2003 , 68, 23-9	3.9	6
26	The role of transgenic mouse models in carcinogen identification. <i>Environmental Health Perspectives</i> , 2003 , 111, 444-54	8.4	115
25	Inversion of chromosome 12 and lineage promiscuity in hematologic malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2004 , 148, 91-103		1

(2014-2005)

24	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. <i>Blood</i> , 2005 , 106, 3532-7	2.2	28
23	RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2005 , 19, 415-9	10.7	46
22	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. <i>Leukemia</i> , 2005 , 19, 1536-42	10.7	199
21	The molecular pathogenesis of acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 56, 195-221	7	54
20	Kinases as drug discovery targets in hematologic malignancies. Current Molecular Medicine, 2005, 5, 625	5-4.3	26
19	RAD51, genomic stability, and tumorigenesis. <i>Cancer Letters</i> , 2005 , 218, 127-39	9.9	91
18	Molecular genetics of acute myeloid leukemia. 298-338		
17	Cooperativity between Rad51 and C/EBP family transcription factors modulates basal and Tat-induced activation of the HIV-1 LTR in astrocytes. <i>Journal of Cellular Physiology</i> , 2006 , 207, 605-13	7	18
16	K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. <i>Cancer</i> , 2006 , 106, 950-6	6.4	87
15	Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. <i>Molecular and Cellular Biology</i> , 2007 , 27, 4238-47	4.8	229
14	Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells. <i>Experimental Hematology</i> , 2007 , 35, 1231-9	3.1	14
13	Acute Myelogenous Leukemia. Cancer Treatment and Research, 2010,	3.5	
12	Ubiquitin on ras: warden or partner in crime?. Science Signaling, 2011, 4, pe12	8.8	7
11	Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011055	3.2	4
10	Targeting oncogenic Ras signaling in hematologic malignancies. <i>Blood</i> , 2012 , 120, 3397-406	2.2	142
9	RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. <i>International Journal of Hematology</i> , 2012 , 95, 509-15	2.3	25
8	Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 2012, 21, 283-96	24.3	862
7	RAD51 G135C gene polymorphism and risk of colorectal cancer in Kashmir. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 264-8	2	11

6	The Emerging Role of Ras Pathway Signaling in Pediatric Cancer. Cancer Research, 2020, 80, 5155-5163	10.1	4
5	Receptor tyrosine kinase alterations in AML - biology and therapy. <i>Cancer Treatment and Research</i> , 2010 , 145, 85-108	3.5	9
4	Cytogenetic and Molecular Pathology of Pediatric Cancer. 2009 , 99-171		1
3	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402		1
2	Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. <i>Blood</i> , 2000 , 96, 1655-1669	2.2	11
1	Acute Myeloid Leukemias with Normal Cytogenetics. <i>Molecular Pathology Library</i> , 2010 , 449-462		